185 related articles for article (PubMed ID: 15984343)
1. Efficacy and safety of a feline immunodeficiency virus vaccine.
Huang C; Conlee D; Loop J; Champ D; Gill M; Chu HJ
Anim Health Res Rev; 2004 Dec; 5(2):295-300. PubMed ID: 15984343
[TBL] [Abstract][Full Text] [Related]
2. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats.
Kusuhara H; Hohdatsu T; Okumura M; Sato K; Suzuki Y; Motokawa K; Gemma T; Watanabe R; Huang C; Arai S; Koyama H
Vet Microbiol; 2005 Jul; 108(3-4):155-65. PubMed ID: 15899558
[TBL] [Abstract][Full Text] [Related]
3. Lack of protection against feline immunodeficiency virus infection among domestic cats in New Zealand vaccinated with the Fel-O-Vax® FIV vaccine.
Stickney A; Ghosh S; Cave NJ; Dunowska M
Vet Microbiol; 2020 Nov; 250():108865. PubMed ID: 33045631
[TBL] [Abstract][Full Text] [Related]
4. Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax
Westman M; Yang D; Green J; Norris J; Malik R; Parr YA; McDonald M; Hosie MJ; VandeWoude S; Miller C
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809232
[TBL] [Abstract][Full Text] [Related]
5. Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate.
Pu R; Coleman J; Coisman J; Sato E; Tanabe T; Arai M; Yamamoto JK
J Feline Med Surg; 2005 Feb; 7(1):65-70. PubMed ID: 15686976
[TBL] [Abstract][Full Text] [Related]
6. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
[TBL] [Abstract][Full Text] [Related]
7. Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection.
Hofmann-Lehmann R; Holznagel E; Aubert A; Ossent P; Reinacher M; Lutz H
Vet Immunol Immunopathol; 1995 May; 46(1-2):127-37. PubMed ID: 7618252
[TBL] [Abstract][Full Text] [Related]
8. The protective rate of the feline immunodeficiency virus vaccine: An Australian field study.
Westman ME; Malik R; Hall E; Harris M; Norris JM
Vaccine; 2016 Sep; 34(39):4752-4758. PubMed ID: 27522177
[TBL] [Abstract][Full Text] [Related]
9. Diagnosing feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV) infection: an update for clinicians.
Westman ME; Malik R; Norris JM
Aust Vet J; 2019 Mar; 97(3):47-55. PubMed ID: 30809813
[TBL] [Abstract][Full Text] [Related]
10. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates.
Pu R; Coleman J; Omori M; Arai M; Hohdatsu T; Huang C; Tanabe T; Yamamoto JK
AIDS; 2001 Jul; 15(10):1225-37. PubMed ID: 11426067
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats.
Matteucci D; Poli A; Mazzetti P; Sozzi S; Bonci F; Isola P; Zaccaro L; Giannecchini S; Calandrella M; Pistello M; Specter S; Bendinelli M
J Virol; 2000 Dec; 74(23):10911-9. PubMed ID: 11069985
[TBL] [Abstract][Full Text] [Related]
12. Feline immunodeficiency virus model for designing HIV/AIDS vaccines.
Yamamoto JK; Sanou MP; Abbott JR; Coleman JK
Curr HIV Res; 2010 Jan; 8(1):14-25. PubMed ID: 20210778
[TBL] [Abstract][Full Text] [Related]
13. Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.
Sahay B; Yamamoto JK
Viruses; 2018 May; 10(5):. PubMed ID: 29789450
[TBL] [Abstract][Full Text] [Related]
14. Experimental vaccine protection against feline immunodeficiency virus.
Yamamoto JK; Okuda T; Ackley CD; Louie H; Pembroke E; Zochlinski H; Munn RJ; Gardner MB
AIDS Res Hum Retroviruses; 1991 Nov; 7(11):911-22. PubMed ID: 1662057
[TBL] [Abstract][Full Text] [Related]
15. Duration of antibody response following vaccination against feline immunodeficiency virus.
Westman ME; Malik R; Hall E; Harris M; Hosie MJ; Norris JM
J Feline Med Surg; 2017 Oct; 19(10):1055-1064. PubMed ID: 27770018
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.
Gupta S; Leutenegger CM; Dean GA; Steckbeck JD; Cole KS; Sparger EE
J Virol; 2007 Jan; 81(2):465-73. PubMed ID: 17079309
[TBL] [Abstract][Full Text] [Related]
17. Vaccination of cats against feline immunodeficiency virus (FIV): a matter of challenge.
Hesselink W; Sondermeijer P; Pouwels H; Verblakt E; Dhore C
Vet Microbiol; 1999 Sep; 69(1-2):109-10. PubMed ID: 10515278
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection.
Coleman JK; Pu R; Martin M; Sato E; Yamamoto JK
AIDS; 2005 Sep; 19(14):1457-66. PubMed ID: 16135898
[TBL] [Abstract][Full Text] [Related]
19. [Vaccination of cats against infection with feline leukemia virus (FeLV): first recombinant vaccine and the effect of a pre-existing infection with feline immunodeficiency virus (FIV)].
Hofmann-Lehmann R; Aubert A; Wolfensberger C; Cronier J; Lutz H
Schweiz Arch Tierheilkd; 1994; 136(10):340-51. PubMed ID: 7801087
[TBL] [Abstract][Full Text] [Related]
20. Utilization of Feline ELISpot to Evaluate the Immunogenicity of a T Cell-Based FIV MAP Vaccine.
Sahay B; Aranyos AM; McAvoy A; Yamamoto JK
Methods Mol Biol; 2018; 1808():197-219. PubMed ID: 29956186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
